Ensuring access to nutrition resources is fundamental to quality cancer care. Early and proactive nutrition care is associated with improved outcomes as patients progress through their cancer journey to cure or palliation. There is a critical need to improve the quality of life and treatment outcomes for cancer patients, particularly regarding the management of cancer cachexia and other side effects. Cancer cachexia poses a major challenge in healthcare as it leads to severe weight loss, muscle atrophy, fatigue, and inflammation, negatively impacting patients' well-being and treatment response. The lack of effective interventions and limited access to appropriate nutrition resources further compound the problem. Our research aims to address these challenges by investigating the potential of functional ingredient Oligo Fucoidan derived from marine seaweed as an adjunctive therapy for patients experiencing cachexia and management of chronic diseases that contribute to cancer risk. Through rigorous scientific research and clinical trials, we aim to demonstrate the effectiveness of Oligo Fucoidan in enhancing anti-tumor immune response, alleviating side effects of cachexia, improving quality of life, and treatment tolerance of patients. By providing a targeted nutritional or supplemental intervention, we hope to fill the existing gap in cancer care. By developing evidence-based solutions, we aim to improve patient outcomes, reduce treatment discontinuation rates, and ultimately contribute to the advancement of public health and healthcare in the field of cancer care and nutrition.
Since 2007, we have been dedicated to researching and developing brown seaweed, resulting in the identification of our Oligo Fucoidan which exhibits unique bi-directional immunomodulation effects with significant benefits in cancer management.
Potential Benefits of Oligo Fucoidan in Cancer Care
- Inhibit proliferation/metastasis of cancer cell
- Inhibit angiogenesis of cancer
- Induce apoptosis of cancer cell
- Prevent tumor progression, alter tumor microenvironment (TME)
- Improve outcome of chemotherapy & radiotherapy
- Reduce side effects of chemotherapy & radiotherapy
- Reduce radiation-induced fibrosis
- Improve cancer cachexia
- Improve diseases control rate (DCR), be used as adjunct therapy supplement alongside conventional oncology treatment (R Randomized double blind placebo control studies
Our claims are supported by extensive peer-reviewed primary research and clinical trials in humans. To date, we have published over 50 scientific papers on the bioactivity and health benefits of Oligo Fucoidan, with over 30 of these papers directly focusing on its relationship to cancer and the immune system while others related to management of chronic diseases that contribute to cancer risk. These publications provide evidence of the efficacy of Fucoidan in various aspects, including immune modulation, inhibition of cancer cell proliferation and metastasis, induction of apoptosis, prevention of tumor progression, improvement of chemotherapy and radiotherapy outcomes, reduction of side effects, and improvement of cancer cachexia.
Milestone in the Research Journey
One significant milestone in our research journey occurred in 2017 when we successfully completed the first double-blind, randomized controlled trial at Kaohsiung Medical University. This landmark trial specifically evaluated the efficacy of Low-Molecular-Weight Fucoidan (OliFuco® Oligo Fucoidan) as a supplemental therapy in metastatic colorectal cancer patients. The trial conclusively demonstrated the effectiveness of Fucoidan in enhancing the disease control rate among these patients. The results of this trial were subsequently published in the esteemed article titled "Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial."
Additionally, combined of chemotherapeutic drug cisplatin and Hi-Q fucoidan treatment has been shown to increase the survival rate of patients with lung cancer in Taiwan (peer-reviewed research, 2018). Oligo Fucoidan also has attained its inclusion in the Dictionary of Drugs of the U.S. National Cancer Institute (NCI) (Code C170752). Additionally, we continue collaboration with esteemed research institutions, universities, and hospitals both locally in Taiwan and internationally, include the National Health Research Institutes, National Taiwan University Hospital, Taipei Medical University, Argentina's National Atomic Energy Commission, University of Buenos Aires, Shanghai Zhongshan Hospital of Fudan University, and Veterinary Cancer Center USA.
Hi-Q’s Publications in Canncer Care Research
|Therapeutic Efficacy, Radiotoxicity and Abscopal Effect of BNCT at the RA-3 Nuclear Reactor Employing Oligo-Fucoidan and Glutamine as Adjuvants in an Ectopic Colon Cancer Model in Rats
|Biochemical characterization and anti-cancer activity of tangential flow filtration system assisted purification of fucoglucan from Laminaria japonica
|WNK1–OSR1 Signaling Regulates Angiogenesis-Mediated Metastasis towards Developing a Combinatorial Anti-Cancer Strategy
|Oligo‑Fucoidan Supplementation Enhances the Effect of Olaparib on Preventing Metastasis and Recurrence of Triple‑Negative Breast Cancer in Mice
|Fucoidan Increased the Sensitivity to Gefitinib in Lung Cancer Cells Correlates with Reduction of TGFβ-Mediated Slug Expression
|The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study
|Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer
|Enhanced Cellular Uptake in an Electrostatically Interacting Fucoidan-L-Arginine Fiber Complex
|Fucoidan Inhibits the Progression of Hepatocellular Carcinoma via Causing lncRNA LINC00261 Overexpression
|Low Molecular Weight Fucoidan Inhibits Hepatocarcinogenesis and Nonalcoholic Fatty Liver Disease in Zebrafish via ASGR/STAT3/HNF4A Signaling
|Low Molecular Weight Fucoidan Prevents Radiation-Induced Fibrosis and Secondary Tumors in a Zebrafish Model
|Protective Effect of Low‐Molecular‐Weight Fucoidan on Radiation‐Induced Fibrosis Through TGF‐β1/Smad Pathway‐Mediated Inhibition of Collagen I Accumulation
|Radioprotective Effect of Self-Assembled Low Molecular Weight Fucoidan–Chitosan Nanoparticles.
|Oligo-Fucoidan Prevents M2 Macrophage Differentiation and HCT116 Tumor Progression.
|Epigenetic Modification and Differentiation Induction of Malignant Glioma Cells by Oligo-Fucoidan
|Clinical Applications of Fucoidan in Translational Medicine for Adjuvant Cancer Therapy
|The Anti-Tumor Activity of Brown Seaweed Oligo-Fucoidan via lncRNA Expression Modulation in HepG2 Cells
|Fucoidan Inhibits Radiation-Induced Pneumonitis and Lung Fibrosis by Reducing Inflammatory Cytokine Expression in Lung Tissues
|Fucoidan upregulates TLR4/CHOP-mediated caspase-3 and PARP activation to enhance cisplatin-induced cytotoxicity in human lung cancer cells
|Oligo-Fucoidan Prevents IL-6 and CCL2 Production and Cooperates with p53 to Suppress ATM Signaling and Tumor Progression
|Fucoidan Induces Toll-like Receptor 4-Regulated Reactive Oxygen Species and Promotes Endoplasmic Reticulum Stress-Mediated Apoptosis in Lung Cancer
|Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial
|Brown Seaweed Fucoidan Inhibits Cancer Progression by Dual Regulation of mir-29c/ADAM12 and miR-17-5p/PTEN Axes in Human Breast Cancer Cells
|Combined Administration of Fucoidan Ameliorates Tumor and Chemotherapy-Induced Skeletal Muscle Atrophy in Bladder Cancer-Bearing Mice
|Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia
|Fucoidan Elevates MicroRNA-29b to Regulate DNMT3B-MTSS1 Axis and Inhibit EMT in Human Hepatocellular Carcinoma Cells
|Fucoidan Inhibition of Lung Cancer in vivo and in vitro: Role of the Smurf2-Dependent Ubiquitin Proteasome Pathway in TGFβ Receptor Degradation
|Fucoidan Induces Changes in the Epithelial to Mesenchymal Transition and Decreases Metastasis by Enhancing Ubiquitin-Dependent TGFβ Receptor Degradation in Breast Cancer